DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) Director John K. Bell bought 20,000 shares of the company’s stock in a transaction dated Thursday, November 16th. The shares were purchased at an average price of $0.81 per share, with a total value of $16,200.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Shares of DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) opened at $0.86 on Monday. DelMar Pharmaceuticals, Inc. has a 1-year low of $0.78 and a 1-year high of $5.39.

DelMar Pharmaceuticals (NASDAQ:DMPI) last issued its quarterly earnings data on Monday, November 13th. The company reported ($0.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.01). analysts anticipate that DelMar Pharmaceuticals, Inc. will post -0.61 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “DelMar Pharmaceuticals, Inc. (DMPI) Director Buys $16,200.00 in Stock” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at

An institutional investor recently bought a new position in DelMar Pharmaceuticals stock. Franklin Resources Inc. acquired a new position in DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 1,076,923 shares of the company’s stock, valued at approximately $2,477,000. 8.26% of the stock is currently owned by institutional investors and hedge funds.

DMPI has been the subject of a number of analyst reports. Dawson James reiterated a “buy” rating on shares of DelMar Pharmaceuticals in a report on Tuesday, August 8th. Maxim Group restated a “hold” rating on shares of DelMar Pharmaceuticals in a report on Monday, September 11th. Finally, HC Wainwright set a $12.00 price objective on shares of DelMar Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, October 16th.

DelMar Pharmaceuticals Company Profile

DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.

Insider Buying and Selling by Quarter for DelMar Pharmaceuticals (NASDAQ:DMPI)

Receive News & Stock Ratings for DelMar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.